Company / Free Cash Flow
Edgewise Therapeutics, Inc. Free Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$144.1M
FY2025
5-year range
-$144.1M / -$34.2M
FY2021-FY2025
Trend
-30.6%
vs FY2024
Sector context
#128 of 194
Health Care
What the data says
At -$144M, Edgewise Therapeutics, Inc.'s free cash flow ranks #128 of 194 in the Health Care sector. Free Cash Flow has declined for 5 consecutive years, from -$15M in FY2020 to -$144M in FY2025.
Based on SEC 10-K filings.
-$144M in FY2025.
Declined from -$98M to -$144M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#128 of 194 in Health CareTop 66% of 194This company -$144.1M Sector average $470.8M
▼
-130.6% below sector average
Key checks
Key Insights
- Edgewise Therapeutics, Inc.'s free cash flow has declined for 5 consecutive years.
- In FY2025, free cash flow decreased 30.6% year-over-year.
- Ranks #128 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$144.1M | -30.6% |
| FY2024 | -$110.3M | -12.9% |
| FY2023 | -$97.7M | -67.9% |
| FY2022 | -$58.2M | -70.2% |
| FY2021 | -$34.2M | -130.3% |
| FY2020 | -$14.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026